Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage

• Published in: Journal of the American Society of Nephrology Vol. 26; no. 12; pp. 3045 - 3059
• Main Authors: Tomlinson, James A P, Caplin, Ben, Boruc, Olga, Bruce-Cobbold, Claire, Cutillas, Pedro, Dormann, Dirk, Faull, Peter, Grossman, Rebecca C, Khadayate, Sanjay, Mas, Valeria R, Nitsch, Dorothea D, Wang, Zhen, Norman, Jill T, Wilcox, Christopher S, Wheeler, David C, Leiper, James
• Format: Journal Article
• Language: English
• Published: United States American Society of Nephrology 01-12-2015
• Subjects: Acute Kidney Injury - etiology; Acute Kidney Injury - metabolism; Acute Kidney Injury - pathology; Adult; Allografts - metabolism; Amidohydrolases - genetics; Amidohydrolases - metabolism; Animals; Arginine - analogs & derivatives; Arginine - metabolism; Basic Research; Collagen Type I - urine; Collagen Type I, alpha 1 Chain; Female; Folic Acid - adverse effects; Gene Expression; Glomerular Filtration Rate; Humans; Kidney Transplantation; Kidney Tubules, Proximal - enzymology; Kidney Tubules, Proximal - pathology; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Nitric Oxide - metabolism; RNA, Messenger - metabolism; Transaminases - genetics; Transaminases - metabolism; Ureteral Obstruction - complications; Uromodulin - urine; nitric oxide; fibrosis; proximal tubule; chronic renal failure; transgenic mouse; pathophysiology of renal disease and progression
• ISSN: 1046-6673; 1533-3450
• DOI: 10.1681/ASN.2014030280

Nitric oxide (NO) production is diminished in many patients with cardiovascular and renal disease. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthesis, and elevated plasma levels of ADMA are associated with poor outcomes. Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is a methylarginine-metabolizing enzyme that reduces ADMA levels. We reported previously that a DDAH1 gene variant associated with increased renal DDAH1 mRNA transcription and lower plasma ADMA levels, but counterintuitively, a steeper rate of renal function decline. Here, we test the hypothesis that reduced renal-specific ADMA metabolism protects against progressive renal damage. Renal DDAH1 is expressed predominately within the proximal tubule. A novel proximal tubule-specific Ddah1 knockout (Ddah1(PT-/-)) mouse demonstrated tubular cell accumulation of ADMA and lower NO concentrations, but unaltered plasma ADMA concentrations. Ddah1(PT-/-) mice were protected from reduced kidney tissue mass, collagen deposition, and profibrotic cytokine expression in two independent renal injury models: folate nephropathy and unilateral ureteric obstruction. Furthermore, a study of two independent kidney transplant cohorts revealed higher levels of human renal allograft methylarginine-metabolizing enzyme gene expression associated with steeper function decline. We also report an association among DDAH1 expression, NO activity, and uromodulin expression supported by data from both animal and human studies, raising the possibility that kidney DDAH1 expression exacerbates renal injury through uromodulin-related mechanisms. Together, these data demonstrate that reduced renal tubular ADMA metabolism protects against progressive kidney function decline. Thus, circulating ADMA may be an imprecise marker of renal methylarginine metabolism, and therapeutic ADMA reduction may even be deleterious to kidney function.